|
gptkbp:instance_of
|
gptkb:biotechnology
gptkb:pharmaceuticals
|
|
gptkbp:acquired_by
|
gptkb:Amgen
|
|
gptkbp:acquisition
|
Merger and acquisition
$10.4 billion
|
|
gptkbp:acquisition_year
|
gptkb:2013
|
|
gptkbp:allies
|
gptkb:Yes
other biotech firms
|
|
gptkbp:annual_report
|
available online
|
|
gptkbp:business_model
|
Biopharmaceuticals
biopharmaceuticals
|
|
gptkbp:ceo
|
gptkb:Tony_Coles
gptkb:Robert_A._Figlin
|
|
gptkbp:clinical_trial
|
gptkb:Oncology
gptkb:Yes
Active
Ongoing
Published
ongoing
Innovative
Phase III
various hospitals
innovative therapies
Phase 1, Phase 2, Phase 3
published in journals
published in medical journals
various stages of development
Phase I, II, III trials
I, II, III
|
|
gptkbp:collaborations
|
gptkb:Yes
Academic institutions
academic institutions
|
|
gptkbp:community_engagement
|
patient advocacy groups
Philanthropic initiatives
|
|
gptkbp:defunct
|
gptkb:2013
|
|
gptkbp:drug_approval_process
|
follows regulatory guidelines
|
|
gptkbp:economic_development
|
Sustained
expansion in oncology market
|
|
gptkbp:employees
|
Approximately 300
500+
|
|
gptkbp:financial_performance
|
gptkb:Strong
reported quarterly
|
|
gptkbp:financial_reports
|
quarterly earnings
|
|
gptkbp:financial_support
|
available for patients.
|
|
gptkbp:focus
|
gptkb:cancer_treatment
Cancer treatment
|
|
gptkbp:founded
|
gptkb:1992
|
|
gptkbp:founder
|
gptkb:Dr._John_D._Mendelsohn
gptkb:Dr._R._Scott_Greer
|
|
gptkbp:funding
|
gptkb:Significant
secured from investors
|
|
gptkbp:global_presence
|
gptkb:Yes
|
|
gptkbp:grants
|
Available
|
|
gptkbp:has_advisory_board
|
gptkb:Yes
experts in oncology
|
|
gptkbp:head_of_state
|
Active
|
|
gptkbp:headcount
|
300+
|
|
gptkbp:headquarters
|
gptkb:California
gptkb:San_Francisco,_California
|
|
gptkbp:healthcare
|
gptkb:Yes
Kyprolis (2012)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Onyx Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:biotechnology
gptkb:pharmaceuticals
|
|
gptkbp:instruction_set
|
Diverse
Various oncology drugs
|
|
gptkbp:invention
|
gptkb:Multiple
multiple drug formulations
|
|
gptkbp:investment
|
gptkb:public_company
Active
various venture capital firms
Various venture capital firms
regular communications
R& D
|
|
gptkbp:investment_focus
|
gptkb:Oncology
|
|
gptkbp:investor_meetings
|
gptkb:Regular
held regularly
|
|
gptkbp:key_people
|
gptkb:Tony_Coles
|
|
gptkbp:leadership
|
Experienced executives
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market
|
conducted regularly
Conducted
|
|
gptkbp:market_cap
|
$10 billion (2013)
$9 billion (2013)
|
|
gptkbp:market_launch
|
gptkb:2012
Kyprolis (2012)
|
|
gptkbp:market_position
|
global
|
|
gptkbp:marketing_strategy
|
Targeted therapies
Growth and innovation
focus on oncology
|
|
gptkbp:net_income
|
$300 million (2012)
|
|
gptkbp:partnership
|
research institutions
|
|
gptkbp:partnerships
|
gptkb:Open
gptkb:Yes
various pharmaceutical companies
Various pharmaceutical companies
|
|
gptkbp:pipeline_products
|
various investigational drugs
|
|
gptkbp:product
|
Ongoing
|
|
gptkbp:product_type
|
Prescription medication
|
|
gptkbp:products
|
gptkb:Kyprolis
|
|
gptkbp:publications
|
Numerous
research findings
|
|
gptkbp:regulatory_compliance
|
Active
approved drugs
adheres to FDA regulations
|
|
gptkbp:related_products
|
gptkb:Carfilzomib
|
|
gptkbp:research
|
Ongoing
|
|
gptkbp:research_areas
|
gptkb:Oncology
Hematology
hematology
ongoing research
Focused on cancer
|
|
gptkbp:research_focus
|
gptkb:Oncology
Multiple myeloma
novel cancer therapies
|
|
gptkbp:revenue
|
$1.2 billion (2012)
$1.1 billion (2012)
|
|
gptkbp:social_responsibility
|
Active
health initiatives
|
|
gptkbp:specialization
|
oncology
|
|
gptkbp:stock_symbol
|
gptkb:ONXX
|
|
gptkbp:strategic_goals
|
expand product pipeline
|
|
gptkbp:subsidiary
|
gptkb:Onyx_Pharmaceuticals,_Inc.
gptkb:Amgen_Inc.
|
|
gptkbp:team
|
experienced executives
|
|
gptkbp:therapeutic_indications
|
multiple myeloma, solid tumors
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.onyx-pharm.com
|
|
gptkbp:bfsParent
|
gptkb:Amgen
|
|
gptkbp:bfsLayer
|
4
|